Development of Pleiotropic TrkB and 5-HT4 Receptor Ligands as Neuroprotective Agents
Molecules · 2024
DOI: 10.3390/molecules29020515 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Mirjana Antonijevic und 11 weiteren Autor:innen. Beteiligte Einrichtung: Normandie University, Unicaen, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), 14000 Caen, France. Hauptthemen laut MEDLINE: Neuroprotective Agents, Neurodegenerative Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission, European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant.
Abstract (Originalsprache)
One common event that is the most detrimental in neurodegenerative disorders, even though they have a complex pathogenesis, is the increased rate of neuronal death. Endogenous neurotrophins consist of the major neuroprotective factors, while brain-derived neurotrophic factor (BDNF) and its high-affinity tyrosine kinase receptor TrkB are described in a number of studies for their important neuronal effects. Normal function of this receptor is crucial for neuronal survival, differentiation, and synaptic function. However, studies have shown that besides direct activation, the TrkB receptor can be transactivated via GPCRs. It has been proven that activation of the 5-HT4 receptor and transactivation of the TrkB receptor have a positive influence on neuronal differentiation (total dendritic length, number of primary dendrites, and branching index). Because of that and based on the main structural characteristics of LM22A-4, a known activator of the TrkB receptor, and RS67333, a partial 5-HT4 receptor agonist, we have designed and synthesized a small data set of novel compounds with potential dual activities in order to not only prevent neuronal death, but also to induce neuronal differentiation in neurodegenerative disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Normandie University, Unicaen, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), 14000 Caen, France.
- Department of Pharmacology, Medical School, University of Crete, 70013 Heraklion, Greece.
- Institute of Molecular Biology & Biotechnology, Foundation of Research & Technology-Hellas, 70013 Heraklion, Greece.
- IGF, Univ Montpellier, CNRS, INSERM, 34000 Montpellier, France.
- Innoprot S.L, 48160 Derio, Spain.
ORCID-Profile: Audrey Davis, Thomas Curel, Isbaal Ramos, Sylvie Claeysen, Patrick Dallemagne, Achille Gravanis, Ioannis Charalampopoulos, Christophe Rochais
Förderung
- European Commission
- European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant
Zitieren
APA
Antonijevic, M., Charou, D., Davis, A., Curel, T., Valcarcel, M., Ramos, I., Villacé, P., Claeysen, S., Dallemagne, P., Gravanis, A., Charalampopoulos, I., & Rochais, C. (2024). Development of Pleiotropic TrkB and 5-HT4 Receptor Ligands as Neuroprotective Agents. Molecules. https://doi.org/10.3390/molecules29020515
Vancouver
Antonijevic M, Charou D, Davis A, Curel T, Valcarcel M, Ramos I, et al. Development of Pleiotropic TrkB and 5-HT4 Receptor Ligands as Neuroprotective Agents. Molecules. 2024. doi:10.3390/molecules29020515
BibTeX
@article{Antonijevic2024,
author = {Antonijevic, Mirjana and Charou, Despoina and Davis, Audrey and Curel, Thomas and Valcarcel, Maria and Ramos, Isbaal and Villacé, Patricia and Claeysen, Sylvie and Dallemagne, Patrick and Gravanis, Achille and Charalampopoulos, Ioannis and Rochais, Christophe},
title = {Development of Pleiotropic TrkB and 5-HT4 Receptor Ligands as Neuroprotective Agents},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29020515}
}
EUVIMED